aTyr Pharma, Inc. Common Stock
ATYRaTyr Pharma, Inc. is a biotechnology company focused on developing innovative therapies targeting rare and severe diseases, particularly those involving neuroinflammation and immune modulation. The company's approach involves designing molecules that can restore or maintain healthy cellular functions, with an emphasis on the nervous and immune systems.
Company News
Hagens Berman is pursuing a securities class action lawsuit against aTyr Pharma after its flagship drug trial failed, causing an 83% stock price collapse. The lawsuit alleges the company misrepresented the efficacy of its drug Efzofitimod and concealed material adverse facts about its performance.
A class action lawsuit has been filed against aTyr Pharma alleging false and misleading statements about the efficacy of their drug Efzofitimod, with investors having until December 8, 2025 to apply as lead plaintiff.
Rosen Law Firm alerts ATyr Pharma investors about a securities class action lawsuit deadline on December 8, 2025, related to allegedly misleading statements about the effectiveness of the drug Efzofitimod.
Rosen Law Firm is pursuing a securities class action against aTyr Pharma for allegedly providing false and misleading statements about the efficacy of their drug Efzofitimod during the period of January 16, 2025 to September 12, 2025.
A class action lawsuit has been filed against aTyr Pharma alleging false and misleading statements about the efficacy of their drug Efzofitimod during the period of January 16-September 12, 2025.
